Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹6.82
-₹0.12(-1.73%)
At close: 4:00 PM EDT
₹6.82
-₹0.12(-1.73%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹14.14
Previous CloseN/A
Volume22.89K
Average Volume (3M)39.13K
Market Cap
₹348.20M
Enterprise Value₹471.28M
Total Cash (Recent Filing)₹6.97M
Total Debt (Recent Filing)₹97.47M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API Manufacturing ModelLasa's core B2B API and intermediate manufacturing addresses stable, recurring demand from formulators and finished-dosage manufacturers across therapeutic categories. This business model creates repeat revenue, technical barriers to entry and long sales cycles that support durable customer relationships if quality and compliance are maintained.
Manageable Leverage (low Debt)A low debt-to-equity ratio (~0.20) gives the company balance-sheet flexibility to absorb operating volatility, refinance or access working capital without large interest burdens. That structural conservatism materially reduces near-term solvency pressure and supports strategic options during recovery or restructuring.
Proven Ability To Generate Operating Cash HistoricallyPrior periods of strong operating cash flow (notably FY2021 and positive in FY2024) show the business can produce cash when utilization, pricing and cost control align. This historical capability implies management can restore cash generation through operational fixes, capacity use and customer re-engagement over months.
Bears Say
Severe Revenue DeclineA ~74% YoY revenue collapse is structurally damaging: it erodes scale economics, weakens supplier/customer relationships and leaves fixed costs poorly covered. Restoring revenue requires rebuilding orders or new market entry, a multi-quarter process with execution risk and potential margin pressure during recovery.
Deeply Negative MarginsPersistently negative gross and net margins signal selling below cost, major write-downs, or sustained cost-price mismatch. Such structural erosion destroys profitability and equity, limits reinvestment capacity, and requires substantive pricing, input-cost or product-mix fixes to reach sustainable margins again.
Weak And Inconsistent Cash GenerationMaterial negative operating cash flow (~-81M) and pressured free cash flow reduce internal funding for working capital and capex, increasing reliance on external financing. Over months, this limits strategic flexibility and raises solvency risk if losses persist or access to capital tightens.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹14.14 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹348.20M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 15 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on May 29, 2026. The company reported -₹0.83 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.83.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.83 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―